% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • alphamojo alphamojo Oct 30, 2010 12:58 PM Flag

    Liposome Encapsulation/NanoBlog/Merck

    Odaat's "educated guess" that a Merck - Celsion relationship may be developing may have merit. Go to Google and search for current items on Thermodox. A blog item from "Encapsula's Scientific Blog" titled "Liposome: Encapsula's Scientific Blog: Celsion Announces..." should be the latest item and the summary should start with "Thermodox has also...". Click on the Blog which takes you to an Encapsula Nano Sciences blog dated October 29, 2010 titled: "Celsion Annoounces Thermodox's..." which is essentially a summary of Celsion's October 19th PRNewswire-First Call concerning the recent HIFU abstracts from the October 17-20 Conference presentations. Now scoll down while watching the Journal of Liposome articles appearing on the right towards the bottom of the third page where you will see the last article under the heading ClinicalTrials-gov:liposome. Beneath this heading you will see several short lines beginning with "MK-4827 in Combination..." Click on this item and you will be sent to a page titled:
    "MK-4827 in Combination With Pepylated Liposomal Doxorrubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)" Yes, it isn't Liver Cancer but it is very current information concerning Merck using Liposomal Doxorubicin to attack solid tumors. processed the record on October 28, 2010. The four (4) page Trial announcement is sponsored by Merck, was "Verified by Merck, October 2010" and was first received by on October 22, 2010. Granted, every pharma/biopharma company addressing any form of cancer, certainly any form involving solid tumors is probably using Doxorubicin in some way. But this still may be a clue that Merck and Celsion have more than a casual relationship. Quiz question: Just exactly what does "Pegylated" mean. I have avoided Celsion shares like the plague for sometime. The money to be made in this market is in high-priced stocks or their options, selected small cap techs or likely takeouts such as PAY (NYSE). But I am warming up to Celsion again, especially below $3.
    Best to All - it has been a long time.
    Alphamojo (formerly Mojobeta before Obama was elected).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.25-0.05(-3.85%)Feb 5 3:59 PMEST